Current treatment for nerve injury-induced neuropathic pain, one of the most common clinical syndromes, is limited. Understanding pathological changes related to this disorder may help shift treatment strategies from symptomatic relief to neuropathic pain-specific novel therapies. Peripheral nerve injury-induced changes in the expression of receptors, enzymes, and voltage-dependent ion channels in the dorsal root ganglion (DRG) contribute to neuropathic pain genesis. However, the molecular mechanisms of how nerve injury causes these changes are still elusive. Recent studies suggest that the mechanism for gene regulation involves epigenetic modification, such as histone methylation. G9a, a histone methyltransferase, primarily catalyzes histone H3 lysine 9 monomethylation (H3K9me1) and dimethylation (H3K9me2) and is a key regulator of gene expression. Our preliminary data indicate that a nerve injury-induced increase in DRG G9a may be responsible for neuropathic pain by governing the expression of DRG mu opioid receptor (MOR) and kappa opioid receptor (KOR) genes. This proposal will determine whether and how DRG G9a is up-regulated following peripheral nerve injury and whether and how G9a contributes to pain hypersensitivity under neuropathic pain conditions.
In Aim 1, we will determine whether pharmacological inhibition or genetic knockdown of DRG G9a attenuates nerve injury-induced pain hypersensitivity during the development and maintenance periods and whether overexpression of DRG G9a leads to major symptoms of neuropathic pain.
In Aim 2, we will observe the expression of G9a and C/EBP? and the levels of H3K9me1 and H3K9me2 in the DRG after peripheral nerve injury. We will also examine whether nerve injury-induced up-regulation of DRG G9a is attributed to an increase in the binding activity of C/EBP? to the G9a gene promoter in the DRG under neuropathic pain conditions.
In Aim 3, we will examine whether and how G9a participates in the nerve injury- induced down-regulation of MOR and KOR in the injured DRG. We will first observe whether G9a binds to the promoter and 5'-end regulatory regions of MOR and KOR genes and whether these binding activities are increased in the injured DRG neurons after the fourth spinal nerve injury (SNL). We will then define whether G9a contributes to the SNL-induced down-regulation of DRG MOR and KOR by blocking the access of the transcriptional factor cyclic AMP response element binding protein to its binding motifs within these two genes. Finally, we will determine whether blocking the SNL-induced increase in DRG G9a rescues the downregulation of MOR and KOR in the injured DRG, reduces primary afferent neurotransmitter release, restores the decrease of opioid analgesia, and attenuates opioid tolerance development. These studies will not only advance our understanding of the epigenetic mechanisms of neuropathic pain but will also open a door to develop a new strategy for the prevention and treatment of this disorder.

Public Health Relevance

The proposed studies will test the novel hypothesis that peripheral nerve injury-induced an increase in G9a, a key regulator of gene expression, in the injured dorsal root ganglion may contribute to the development and maintenance of neuropathic pain by governing the expression of mu and kappa opioid receptors in the dorsal root ganglion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS094664-01A1
Application #
9102654
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Oshinsky, Michael L
Project Start
2016-02-01
Project End
2021-01-31
Budget Start
2016-02-01
Budget End
2017-01-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Rutgers University
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
078795851
City
Newark
State
NJ
Country
United States
Zip Code
Mo, Kai; Wu, Shaogen; Gu, Xiyao et al. (2018) MBD1 Contributes to the Genesis of Acute Pain and Neuropathic Pain by Epigenetic Silencing of Oprm1 and Kcna2 Genes in Primary Sensory Neurons. J Neurosci 38:9883-9899
Li, Q B; Chang, L; Ye, F et al. (2018) Role of spinal cyclooxygenase-2 and prostaglandin E2 in fentanyl-induced hyperalgesia in rats. Br J Anaesth 120:827-835
Cai, Weihua; Wu, Shaogen; Pan, Zhiqiang et al. (2018) Disrupting interaction of PSD-95 with nNOS attenuates hemorrhage-induced thalamic pain. Neuropharmacology 141:238-248
Yuan, Jingjing; Wen, Jing; Wu, Shaogen et al. (2018) Contribution of dorsal root ganglion octamer transcription factor 1 to neuropathic pain after peripheral nerve injury. Pain :
Lutz, Brianna Marie; Wu, Shaogen; Gu, Xiyao et al. (2018) Endothelin type A receptors mediate pain in a mouse model of sickle cell disease. Haematologica 103:1124-1135
Gonzalez, J Patrick; Kyrychenko, Sergii; Kyrychenko, Viktoriia et al. (2017) Small Fractions of Muscular Dystrophy Embryonic Stem Cells Yield Severe Cardiac and Skeletal Muscle Defects in Adult Mouse Chimeras. Stem Cells 35:597-610
Xu, Bo; Cao, Jing; Zhang, Jun et al. (2017) Role of MicroRNA-143 in Nerve Injury-Induced Upregulation of Dnmt3a Expression in Primary Sensory Neurons. Front Mol Neurosci 10:350
Zhao, Jian-Yuan; Liang, Lingli; Gu, Xiyao et al. (2017) DNA methyltransferase DNMT3a contributes to neuropathic pain by repressing Kcna2 in primary afferent neurons. Nat Commun 8:14712
Sun, Linlin; Zhao, Jian-Yuan; Gu, Xiyao et al. (2017) Nerve injury-induced epigenetic silencing of opioid receptors controlled by DNMT3a in primary afferent neurons. Pain 158:1153-1165
Wang, Shaocheng; Li, Qixian; Fang, Hongwei et al. (2017) Spinal cord stimulation versus other therapies in patients with Refractory Angina: A meta-analysis. Transl Perioper Pain Med 2:31-41

Showing the most recent 10 out of 27 publications